Plerixafor can rescue the outcome of failing chemotherapy-based stem cell mobilization. However, the optimal time for plerixafor injection in this setting has not been determined. This was investigated by retrospective analysis of data from 48 mobilizations with plerixafor, chemotherapy, and granulocyte-colony stimulating factor (G-CSF). The required yield of 2.0 x 10(6) CD34+ cells/kg was collected from 71% of patients; the median total yield was 4.1 x 10(6) CD34+ cells/kg. Patients to whom plerixafor was administered late (>= 15 days) after chemotherapy, after a long duration (>= 13 days) of treatment with G-CSF, or when the white blood cell count was high (>= 20 x 10(9)/L) were mobilized as efficiently as other patients. Plerixafor was s...
Transplantation with 2-5 × 106 mobilized CD34+cells/kg body weight lowers transplantation costs and ...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobi...
Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobi...
Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobi...
PubMed ID: 22609192Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoi...
Mobilized peripheral blood (PB) is the preferred source of stem cells (PBSCs) for autologous stem ce...
Mobilized peripheral blood (PB) is the preferred source of stem cells (PBSCs) for autologous stem ce...
Mobilized peripheral blood (PB) is the preferred source of stem cells (PBSCs) for autologous stem ce...
Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobi...
High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard ...
High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard ...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
Transplantation with 2-5 × 106 mobilized CD34+cells/kg body weight lowers transplantation costs and ...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobi...
Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobi...
Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobi...
PubMed ID: 22609192Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoi...
Mobilized peripheral blood (PB) is the preferred source of stem cells (PBSCs) for autologous stem ce...
Mobilized peripheral blood (PB) is the preferred source of stem cells (PBSCs) for autologous stem ce...
Mobilized peripheral blood (PB) is the preferred source of stem cells (PBSCs) for autologous stem ce...
Plerixafor in conjunction with G-CSF (G-P) is an effective strategy for hematopoietic stem cell mobi...
High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard ...
High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard ...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
Transplantation with 2-5 × 106 mobilized CD34+cells/kg body weight lowers transplantation costs and ...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy foll...